Annovis Bio, Inc. (ANVS)
Stock Price:
$4.30 USD
-0.09 (-2.05%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
29.50M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
6.86M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$4.30 |
| Previous Close |
$4.39 |
| Change ($) |
-0.09 |
| Change (%) |
-2.05% |
| Day's Open |
4.38 |
| Day's Range |
4.15 - 4.45 |
| Day's Volume |
25,322 |
| 52-Week Range |
2.42 - 10.61 |
More Stats
| Market Cap |
29.50M |
| Enterprise Value |
18.38M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.86M |
| Float |
3.77M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6,871 |
| Short Ratio |
0.14 |
| Short % of Float |
0.16% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.28 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
11.12M |
| Net Cash / Share |
1.62 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-21.08% |
| ROE |
-24.85% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.00*
(272.09% upside)
Low
12.0
Current: 4.30
High
20.0
Target: 16.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -1.61 | -0.71 |
| Net Income | -0.99 | -0.71 |
| Shares Outstanding | 0.28 | 0.28 |
| Earnings Per Share | -3.51 | -2.57 |
| Operating Cash Flow | -0.48 | -0.56 |
| Free Cash Flow | -0.48 | -0.56 |
| Cash & Equivalents | 0.00 | 0.04 |
| Total Debt | 0.50 | - |
| Net Cash / Debt | -0.50 | 0.04 |
| Assets | 1.12 | 0.05 |
| Liabilities | 2.62 | 0.57 |
| Book Value | -8.58 | -7.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Annovis Bio, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Maria-Luisa Maccecchini |
Stock Information
| Ticker Symbol |
ANVS |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: ANVS |
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.